



August 30, 2016
Taiho Pharmaceutical Co., Ltd.

**UK's NICE Recommends LONSURF[®] (trifluridine/tipiracil)
As Treatment of Previously Treated Metastatic Colorectal Cancer
- Taiho's Partner Servier to Market LONSURF in UK -**

Taiho Pharmaceutical Co., Ltd. announced on August 30 that the National Institute for Health and Care Excellence (NICE) has issued final guidance recommending LONSURF[®] (trifluridine/tipiracil), within its marketing authorisation, as an option for treating metastatic colorectal cancer, in adults who have had previous treatment with available therapies including fluoropyrimidine - , oxaliplatin - or irinotecan - based chemotherapies, anti - vascular endothelial growth factor (VEGF) agents and anti - epidermal growth factor receptor (EGFR) agents, or when these therapies are not suitable.¹ The full recommendation can be found here:

www.nice.org.uk/guidance/ta405

It was noted in the final guidance that the committee could recommend LONSURF as a cost-effective use of NHS resources for treating metastatic colorectal cancer. Servier UK will market LONSURF in the UK.

LONSURF was originally developed by Taiho Pharmaceutical, and Servier will co-develop and commercialize LONSURF in Europe and other countries outside of the United States, Canada, Mexico and Japan/Asia under a license agreement with Taiho Pharmaceutical.

Servier was granted a marketing authorization for LONSURF in the European Union (EU) from the European Commission (EC) in April 2016. Servier has been working with national health authorities in each country to bring LONSURF to patients who need it as early as possible.

Through partnership with Servier, Taiho Pharmaceutical anticipates that LONSURF, as a new treatment option, will make an even greater contribution to cancer patients in Europe and other countries.

About Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the UK² and Europe.³ In 2012, 215,000 people died from the disease across Europe³, with 16,200 of those people being from the UK.³

There were around 41,100 new cases of CRC in the UK in 2013.² CRC is the fourth most common cancer in the UK (2013), with 1 in 14 men and 1 in 19 women diagnosed with CRC during their lifetime.²

Approximately 25% of patients with CRC present with metastases at initial diagnosis and almost 50% of patients with CRC will develop metastases.³ When diagnosed at its earliest stage, more than 9 in 10 people with CRC will survive their disease for five years or more, compared with fewer than 1 in 10 people when diagnosed at the latest stage.²

About LONSURF® (trifluridine/tipiracil)

LONSURF is approved in the European Union (EU) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti- EGFR agents.⁴

LONSURF is currently available in Japan for the treatment of unresectable advanced or recurrent CRC and in the United States for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine -, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild- type, an anti-EGFR therapy.⁵⁻⁷ LONSURF is an oral anticancer drug, comprising the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from fluoropyrimidines.^{4,8,9} FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA.^{4,8,9} The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase.^{4,9}

In June 2015, Taiho Pharmaceutical and Servier entered into an exclusive license agreement for the co - development and commercialisation of LONSURF. Under the terms of the agreement, Servier has the rights to co - develop and commercialise LONSURF in Europe and other countries outside of the United States, Canada, Mexico and Japan/ Asia. Taiho Pharmaceutical retains the right to develop and commercialise LONSURF in the United States, Canada, Mexico, and Japan/Asia and to manufacture and supply the product.

About Servier

Servier is a non - listed international pharmaceutical company headquartered in France. With a strong international presence in 148 countries and a turnover of 3.9 billion euro in 2015, Servier employs over 21,200 people worldwide. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiology, oncology, metabolism, neuropsychiatry and rheumatology. Thanks to its governance placed in a non - profit Foundation, the Group reinvests 25% of Servier's products turnover in Research and Development, and all its profits in its growth.

Becoming a key player in oncology is part of Servier's long - term strategy. Currently, there are nine new molecular entities in clinical development in this area, targeting breast and lung cancers and other solid tumors, as well as various leukemias and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks, including cytotoxics, proapoptotics, targeted, immune and cellular therapies.

1. NICE TA405. Available at: www.nice.org.uk/guidance/TA405 Accessed August 2016
2. Cancer Research UK. Bowel Cancer Statistics. Available at: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer> Accessed August 2016
3. Van Cutsem E, et al *Annals of Oncology* (2014) 25 (suppl 3): iii1 - iii9.
4. Lonsurf SPC available at <http://www.medicines.org.uk/emc/medicine/32207> Accessed August 2016
5. FDA News Release. 22 September 2015. Available at: FDA News Release. 22 September 2015. Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm463650.htm> Accessed August 2016
6. Taiho Pharma Press Release 24 March 2014. Available at:

<http://www.taiho.co.jp/english/news/20140324.html> Accessed August 2016

7. Taiho Pharma Press Release 20 March 2015. Available at:

<http://www.taiho.co.jp/english/news/20150320.html> Accessed August 2016

8. Emura T et al. International Journal of Molecular Medicine 2004;13:545 - 49.

9. Lenz HJ, et al. Cancer Treatment Reviews. 2015. 41:777 - 783